JP2016520074A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520074A5 JP2016520074A5 JP2016513321A JP2016513321A JP2016520074A5 JP 2016520074 A5 JP2016520074 A5 JP 2016520074A5 JP 2016513321 A JP2016513321 A JP 2016513321A JP 2016513321 A JP2016513321 A JP 2016513321A JP 2016520074 A5 JP2016520074 A5 JP 2016520074A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen receptor
- chimeric antigen
- specific
- cell
- specific chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002865 immune cell Anatomy 0.000 claims description 34
- 108010005327 CD19-specific chimeric antigen receptor Proteins 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 23
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 13
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 230000004068 intracellular signaling Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 7
- 108020001756 ligand binding domains Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 6
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 208000004736 B-Cell Leukemia Diseases 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000004913 activation Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/892,805 US11603539B2 (en) | 2012-05-25 | 2013-05-13 | Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy |
| PCT/US2013/040766 WO2013176916A1 (en) | 2012-05-25 | 2013-05-13 | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| USPCT/US2013/040766 | 2013-05-13 | ||
| US13/892,805 | 2013-05-13 | ||
| USPCT/US2013/040755 | 2013-05-13 | ||
| PCT/US2013/040755 WO2013176915A1 (en) | 2012-05-25 | 2013-05-13 | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| US201361888259P | 2013-10-08 | 2013-10-08 | |
| US61/888,259 | 2013-10-08 | ||
| PCT/EP2014/059662 WO2014184143A1 (en) | 2013-05-13 | 2014-05-12 | Cd19 specific chimeric antigen receptor and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019037174A Division JP6854307B2 (ja) | 2013-05-13 | 2019-03-01 | Ｃｄ１９特異的キメラ抗原受容体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520074A JP2016520074A (ja) | 2016-07-11 |
| JP2016520074A5 true JP2016520074A5 (OSRAM) | 2017-06-08 |
| JP6491643B2 JP6491643B2 (ja) | 2019-04-03 |
Family
ID=51897790
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513321A Active JP6491643B2 (ja) | 2013-05-13 | 2014-05-12 | Ｃｄ１９特異的キメラ抗原受容体およびその使用 |
| JP2019037174A Active JP6854307B2 (ja) | 2013-05-13 | 2019-03-01 | Ｃｄ１９特異的キメラ抗原受容体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019037174A Active JP6854307B2 (ja) | 2013-05-13 | 2019-03-01 | Ｃｄ１９特異的キメラ抗原受容体およびその使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20210000869A9 (OSRAM) |
| EP (3) | EP4364809A3 (OSRAM) |
| JP (2) | JP6491643B2 (OSRAM) |
| KR (1) | KR102248157B1 (OSRAM) |
| CN (2) | CN105431532B (OSRAM) |
| AU (2) | AU2014267436B2 (OSRAM) |
| BR (1) | BR112015028387B1 (OSRAM) |
| CA (1) | CA2911292C (OSRAM) |
| DK (1) | DK3546572T3 (OSRAM) |
| EA (2) | EA201990575A3 (OSRAM) |
| ES (2) | ES2978123T3 (OSRAM) |
| FI (2) | FI2997141T3 (OSRAM) |
| HR (2) | HRP20221393T1 (OSRAM) |
| HU (2) | HUE067258T2 (OSRAM) |
| LT (2) | LT2997141T (OSRAM) |
| MA (1) | MA38630B2 (OSRAM) |
| MX (1) | MX374681B (OSRAM) |
| MY (1) | MY172897A (OSRAM) |
| PH (1) | PH12015502479B1 (OSRAM) |
| PL (2) | PL2997141T3 (OSRAM) |
| PT (2) | PT2997141T (OSRAM) |
| RS (2) | RS65484B1 (OSRAM) |
| RU (1) | RU2727447C2 (OSRAM) |
| SA (1) | SA515370135B1 (OSRAM) |
| SG (2) | SG11201508805UA (OSRAM) |
| SI (2) | SI2997141T1 (OSRAM) |
| TW (1) | TWI636992B (OSRAM) |
| UA (1) | UA118106C2 (OSRAM) |
| WO (1) | WO2014184143A1 (OSRAM) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6261500B2 (ja) | 2011-07-22 | 2018-01-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ヌクレアーゼ切断特異性の評価および改善 |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN111676196A (zh) | 2012-05-25 | 2020-09-18 | 塞勒克提斯公司 | 工程化异体和免疫抑制耐受性t细胞的方法 |
| US11077144B2 (en) | 2013-05-13 | 2021-08-03 | Cellectis | CD19 specific chimeric antigen receptor and uses thereof |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| PT3066201T (pt) | 2013-11-07 | 2018-06-04 | Massachusetts Inst Technology | Métodos e composições relacionadas com crispr com arng reguladores |
| US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
| JP2017504601A (ja) * | 2013-12-20 | 2017-02-09 | セレクティスＣｅｌｌｅｃｔｉｓ | 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法 |
| WO2015120187A1 (en) | 2014-02-05 | 2015-08-13 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| CA2965224A1 (en) * | 2014-10-24 | 2016-04-28 | Bcrt Holding Bv | T cell-based immunotherapeutics |
| EP3233095A2 (en) * | 2014-12-17 | 2017-10-25 | Cellectis | INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN |
| PT3560953T (pt) | 2014-12-24 | 2024-03-26 | Autolus Ltd | Célula |
| EP3250611B1 (en) | 2015-01-26 | 2021-04-21 | The University of Chicago | Car t-cells recognizing cancer-specific il 13r-alpha2 |
| HK1245287A1 (zh) | 2015-01-26 | 2018-08-24 | The University Of Chicago | IL13RAα2结合剂和其在癌症治疗中的用途 |
| CA2973529A1 (en) | 2015-01-26 | 2016-08-04 | Cellectis | Cll1-specific multi-chain chimeric antigen receptor |
| IL254141B (en) | 2015-02-27 | 2022-07-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) focusing on hematological malignancies, preparations and methods for their use |
| GB201503742D0 (en) * | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| SG11201707089WA (en) | 2015-04-13 | 2017-10-30 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
| GB201507115D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| DK3298033T4 (da) | 2015-05-18 | 2023-10-02 | Tcr2 Therapeutics Inc | Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner |
| CN104829733B (zh) * | 2015-05-25 | 2018-06-05 | 广州百暨基因科技有限公司 | 抗原结合单元稳定的嵌合抗原受体及制备方法与应用 |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| TW202444897A (zh) | 2015-06-25 | 2024-11-16 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| EP3317399B1 (en) * | 2015-06-30 | 2024-06-26 | Cellectis | Methods for improving functionality in nk cell by gene inactivation using specific endonuclease |
| BR112018002600A2 (pt) | 2015-08-11 | 2018-10-23 | Cellectis | células para imunoterapia modificadas para direcionamento ao antígeno cd38 e para inativação do gene cd38 |
| EP3347056A4 (en) * | 2015-09-11 | 2019-02-27 | The Board of Trustees of the Leland Stanford Junior University | BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE / RECEPTOR COUPLES |
| KR20180083313A (ko) | 2015-09-24 | 2018-07-20 | 에이비비트로, 엘엘씨 | Hiv 항체 조성물 및 사용 방법 |
| EP3365356B1 (en) | 2015-10-23 | 2023-06-28 | President and Fellows of Harvard College | Nucleobase editors and uses thereof |
| WO2017075533A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| MX2018005315A (es) * | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | Composiciones y metodos para el tratamiento del cancer. |
| GB201519900D0 (en) * | 2015-11-11 | 2015-12-23 | Ucl Business Plc | Chimeric antigen receptor |
| EP3405481B1 (en) | 2016-01-21 | 2023-01-18 | Pfizer Inc. | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii |
| CN107298715B (zh) | 2016-04-15 | 2021-05-04 | 阿思科力(苏州)生物科技有限公司 | Slit2D2-嵌合抗原受体及其应用 |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CN107446051B9 (zh) * | 2016-05-31 | 2019-02-22 | 上海恒润达生生物科技有限公司 | 靶向cd19的嵌合抗原受体及其用途 |
| CA3029197A1 (en) * | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| AU2017299854A1 (en) | 2016-07-18 | 2019-01-31 | Helix Biopharma Corp. | CAR immune cells directed to carcinoembryonic antigen related cell adhesion molecule 6 to treat cancer |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| EP3497214B1 (en) | 2016-08-09 | 2023-06-28 | President and Fellows of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| WO2018045034A1 (en) * | 2016-08-30 | 2018-03-08 | Promab Biotechnologies, Inc. | Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain |
| MX2019002903A (es) | 2016-09-14 | 2019-07-04 | Janssen Biotech Inc | Receptores de antigeno quimerico que comprenden dominios de tipo iii de fibronectina especificos del bcma y usos de estos. |
| CN108699163B (zh) * | 2016-09-28 | 2021-11-19 | 阿思科力(苏州)生物科技有限公司 | 一种多基因重组嵌合抗原受体分子及其应用 |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| CA3039797A1 (en) * | 2016-10-11 | 2018-04-19 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies and use of cleavage enzyme |
| EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
| JP7778468B2 (ja) | 2016-11-22 | 2025-12-02 | ナショナル ユニバーシティ オブ シンガポール | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
| WO2018165631A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Cancer vaccine |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| EP3592854A1 (en) | 2017-04-13 | 2020-01-15 | Cellectis | New sequence specific reagents targeting ccr5 in primary hematopoietic cells |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| SG10202108528QA (en) | 2017-06-02 | 2021-09-29 | Pfizer | Chimeric antigen receptors targeting flt3 |
| WO2018237022A1 (en) | 2017-06-21 | 2018-12-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| WO2019002633A1 (en) | 2017-06-30 | 2019-01-03 | Cellectis | CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION |
| CA3070100A1 (en) | 2017-07-17 | 2019-01-24 | Janssen Biotech, Inc. | Antigen binding regions against fibronectin type iii domains and methods of using the same |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| CN111757937A (zh) | 2017-10-16 | 2020-10-09 | 布罗德研究所股份有限公司 | 腺苷碱基编辑器的用途 |
| CA3079747A1 (en) * | 2017-10-31 | 2019-05-09 | Allogene Therapeutics, Inc. | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells |
| AU2018359532C9 (en) | 2017-11-01 | 2025-02-13 | Allogene Therapeutics, Inc. | Modified caspase-9 polypeptides and methods of use thereof |
| WO2019106163A1 (en) | 2017-12-01 | 2019-06-06 | Cellectis | Reprogramming of genetically engineered primary immune cells |
| CN111465616B (zh) | 2017-12-06 | 2023-08-01 | 艾克隆株式会社 | 特异性识别恶性b细胞的抗体或其抗原结合片段、包含其的嵌合抗原受体及其用途 |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| TWI800522B (zh) * | 2017-12-23 | 2023-05-01 | 宇越生醫科技股份有限公司 | 醫藥重組受體組成物及方法 |
| KR102780406B1 (ko) | 2018-02-01 | 2025-03-17 | 화이자 인코포레이티드 | Cd70을 표적으로 하는 키메라 항원 수용체 |
| PE20251579A1 (es) | 2018-02-01 | 2025-06-16 | Pfizer | Anticuerpos especificos para cd70 y sus usos |
| CA3034912A1 (en) | 2018-02-28 | 2019-08-28 | Pfizer Inc. | Il-15 variants and uses thereof |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2020011706A1 (en) * | 2018-07-09 | 2020-01-16 | Oslo Universitetssykehus Hf | Two chimeric antigen receptors specifically binding cd19 and igkappa |
| JP7490915B2 (ja) | 2018-08-29 | 2024-05-28 | ナンジン レジェンド バイオテック カンパニー，リミテッド | 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用 |
| US12454694B2 (en) | 2018-09-07 | 2025-10-28 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2020092839A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| EP3887507A1 (en) | 2018-11-30 | 2021-10-06 | Janssen Biotech, Inc. | Gamma delta t cells and uses thereof |
| WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| RU2742000C2 (ru) * | 2019-03-13 | 2021-02-01 | Общество С Ограниченной Ответственностью "Анабион" | Выделенный альтернативный внутриклеточный сигнальный домен химерного антигенного рецептора и включающий его химерный антигенный рецептор |
| MX2021011426A (es) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Metodos y composiciones para editar secuencias de nucleótidos. |
| EP3956349A1 (en) | 2019-04-17 | 2022-02-23 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| JP7672343B2 (ja) * | 2019-04-19 | 2025-05-07 | アロジーン セラピューティクス，インコーポレイテッド | ４ｇ７由来キメラ抗原受容体に対する抗体 |
| ES2961314T3 (es) * | 2019-04-26 | 2024-03-11 | Allogene Therapeutics Inc | Receptores quiméricos de antígeno resistentes a rituximab y usos de los mismos |
| CN114514242A (zh) | 2019-08-27 | 2022-05-17 | 詹森生物科技公司 | 嵌合抗原受体系统及其用途 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN112079934B (zh) * | 2019-12-17 | 2021-01-29 | 合源生物科技(天津)有限公司 | 一种靶向cd19的嵌合抗原受体及其用途 |
| BR112022017419A2 (pt) | 2020-03-03 | 2022-10-18 | Janssen Biotech Inc | Células t gama-delta e usos das mesmas |
| EP4114449A2 (en) | 2020-03-05 | 2023-01-11 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
| MX2022014008A (es) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo. |
| WO2022020456A2 (en) | 2020-07-21 | 2022-01-27 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
| WO2022031597A1 (en) | 2020-08-03 | 2022-02-10 | Kyverna Therapeutics, Inc. | Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same |
| US20230321239A1 (en) | 2020-08-14 | 2023-10-12 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptor t cells for treating autoimmunity |
| CN111944850B (zh) * | 2020-08-28 | 2023-03-31 | 澳门大学 | 表达抗cd22嵌合抗原受体和pd-l1阻断蛋白的细胞的制备方法、表达载体及应用 |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
| WO2022234158A1 (es) * | 2021-05-06 | 2022-11-10 | Institut D'investigacions Biomèdiques August Pi I Sunyer (Idibaps) | Terapia de células t con receptor de antígeno quimérico específico de cd19 |
| WO2022266075A1 (en) | 2021-06-14 | 2022-12-22 | Caribou Biosciences, Inc. | Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain |
| WO2023179766A1 (zh) | 2022-03-24 | 2023-09-28 | 南京传奇生物科技有限公司 | 制备dna文库和检测逆转录病毒整合位点的方法 |
| WO2025051339A1 (en) | 2023-09-05 | 2025-03-13 | Tiber Biotech Srl | SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR |
| EP4574838A1 (en) | 2023-12-21 | 2025-06-25 | Vilnius University | Chimeric antigen receptor (car) with enhanced recruitment of signaling partners |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| JP5312721B2 (ja) * | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Ｃｄ１９特異的再指向免疫細胞 |
| ES2402591T3 (es) * | 2006-08-14 | 2013-05-07 | Xencor Inc. | Anticuerpos optimizados que seleccionan como diana CD19 |
| US20080131415A1 (en) * | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
| SI2211904T1 (sl) * | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| WO2009091826A2 (en) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| WO2010025177A1 (en) * | 2008-08-26 | 2010-03-04 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| WO2012050374A2 (en) * | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| AU2012207356A1 (en) | 2011-01-18 | 2013-08-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| US20120245996A1 (en) | 2011-03-22 | 2012-09-27 | Jonathan Mendez | System and method for intent-based content matching |
| MX359513B (es) * | 2011-03-23 | 2018-10-01 | Hutchinson Fred Cancer Res | Metodo y composiciones para inmunoterapia celular. |
| JP5996630B2 (ja) | 2011-04-05 | 2016-09-21 | セレクティスＣｅｌｌｅｃｔｉｓ | コンパクトｔａｌｅ−ヌクレアーゼを作製する方法及びその使用 |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| EA201490364A1 (ru) * | 2011-07-29 | 2014-08-29 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Костимулирующие рецепторы-переключатели |
| WO2013040557A2 (en) * | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
| CN104159909A (zh) | 2012-02-22 | 2014-11-19 | 宾夕法尼亚大学董事会 | 产生用于癌症治疗的t细胞持续性群体的组合物和方法 |
-
2014
- 2014-05-12 RU RU2015153250A patent/RU2727447C2/ru active
- 2014-05-12 DK DK19161861.0T patent/DK3546572T3/da active
- 2014-05-12 HU HUE19161861A patent/HUE067258T2/hu unknown
- 2014-05-12 FI FIEP14723436.3T patent/FI2997141T3/fi active
- 2014-05-12 SG SG11201508805UA patent/SG11201508805UA/en unknown
- 2014-05-12 MX MX2015015662A patent/MX374681B/es active IP Right Grant
- 2014-05-12 PT PT147234363T patent/PT2997141T/pt unknown
- 2014-05-12 CN CN201480027071.9A patent/CN105431532B/zh active Active
- 2014-05-12 CN CN201910222072.3A patent/CN109897100A/zh active Pending
- 2014-05-12 ES ES19161861T patent/ES2978123T3/es active Active
- 2014-05-12 EP EP24163057.3A patent/EP4364809A3/en active Pending
- 2014-05-12 AU AU2014267436A patent/AU2014267436B2/en active Active
- 2014-05-12 RS RS20240486A patent/RS65484B1/sr unknown
- 2014-05-12 EA EA201990575A patent/EA201990575A3/ru unknown
- 2014-05-12 PL PL14723436.3T patent/PL2997141T3/pl unknown
- 2014-05-12 ES ES14723436T patent/ES2930431T3/es active Active
- 2014-05-12 HU HUE14723436A patent/HUE060901T2/hu unknown
- 2014-05-12 EP EP14723436.3A patent/EP2997141B1/en active Active
- 2014-05-12 MY MYPI2015703966A patent/MY172897A/en unknown
- 2014-05-12 TW TW103116744A patent/TWI636992B/zh active
- 2014-05-12 CA CA2911292A patent/CA2911292C/en active Active
- 2014-05-12 FI FIEP19161861.0T patent/FI3546572T3/fi active
- 2014-05-12 PL PL19161861.0T patent/PL3546572T3/pl unknown
- 2014-05-12 LT LTEPPCT/EP2014/059662T patent/LT2997141T/lt unknown
- 2014-05-12 BR BR112015028387-0A patent/BR112015028387B1/pt active IP Right Grant
- 2014-05-12 WO PCT/EP2014/059662 patent/WO2014184143A1/en not_active Ceased
- 2014-05-12 RS RS20221084A patent/RS63798B1/sr unknown
- 2014-05-12 MA MA38630A patent/MA38630B2/fr unknown
- 2014-05-12 SI SI201431999T patent/SI2997141T1/sl unknown
- 2014-05-12 KR KR1020157035319A patent/KR102248157B1/ko active Active
- 2014-05-12 SG SG10201708896WA patent/SG10201708896WA/en unknown
- 2014-05-12 EA EA201501109A patent/EA036200B1/ru unknown
- 2014-05-12 HR HRP20221393TT patent/HRP20221393T1/hr unknown
- 2014-05-12 SI SI201432070T patent/SI3546572T1/sl unknown
- 2014-05-12 JP JP2016513321A patent/JP6491643B2/ja active Active
- 2014-05-12 HR HRP20240576TT patent/HRP20240576T1/hr unknown
- 2014-05-12 LT LTEP19161861.0T patent/LT3546572T/lt unknown
- 2014-05-12 PT PT191618610T patent/PT3546572T/pt unknown
- 2014-05-12 EP EP19161861.0A patent/EP3546572B9/en active Active
- 2014-12-05 UA UAA201512065A patent/UA118106C2/uk unknown
-
2015
- 2015-10-27 PH PH12015502479A patent/PH12015502479B1/en unknown
- 2015-11-12 SA SA515370135A patent/SA515370135B1/ar unknown
-
2019
- 2019-03-01 JP JP2019037174A patent/JP6854307B2/ja active Active
- 2019-03-15 AU AU2019201818A patent/AU2019201818B2/en active Active
- 2019-03-26 US US16/365,588 patent/US20210000869A9/en not_active Abandoned
-
2023
- 2023-08-17 US US18/451,816 patent/US20240269178A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520074A5 (OSRAM) | ||
| JP7781243B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| KR102763121B1 (ko) | 치료적 면역 세포의 효능의 향상 방법 | |
| JP2018029594A5 (OSRAM) | ||
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe | |
| JP2020509050A5 (OSRAM) | ||
| JP2017535292A5 (OSRAM) | ||
| CN111247241A (zh) | T细胞受体缺陷型嵌合抗原受体t细胞和其使用方法 | |
| JP7577430B2 (ja) | 改変細胞及び方法 | |
| JP2015527070A5 (OSRAM) | ||
| JP2019530431A5 (OSRAM) | ||
| JP2020503891A5 (OSRAM) | ||
| CN110461335A (zh) | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 | |
| RU2015153250A (ru) | Cd19-специфический химерный антигенный рецептор и его применения | |
| JP2017515460A5 (OSRAM) | ||
| JP2017537629A5 (OSRAM) | ||
| JP2018504094A5 (OSRAM) | ||
| JP2018535701A5 (OSRAM) | ||
| JP2017537925A5 (OSRAM) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2016534717A5 (OSRAM) | ||
| JP2019500894A5 (OSRAM) | ||
| JP2017509342A5 (OSRAM) | ||
| JP2017513478A5 (OSRAM) | ||
| JP2017523784A5 (OSRAM) |